- This investment is part of the company’s plan to broaden its Peptide Platform business and exceed €1bn in sales by 2028. CordenPharma has finalised plans for a new The post CordenPharma announces $1bn investment in peptide development...
- The move is said to propel the company’s antibody discovery and engineering offerings, and is in line with its current growth plan. Previously known as Distributed Bio, the The post FairJourney acquires Charles River’s San Francisco site...
- This approval covers all indications of the reference products and the biosimilars are anticipated to be available by June 2025 in the country as per the settlement agreement The post FDA approves Celltrion’s biosimilars for various...
- The oral Factor B inhibitor of the alternative complement pathway is designed for this rare kidney condition with no approved treatments, which significantly impacts young individuals’ lives. The The post EMA’s CHMP...
- The designation is designed to accelerate the development and review of medications that show potential to address serious conditions. Candidates with this designation may qualify for an interaction The post FDA grants fast track status...
- LMU researchers have shown that a particular type of immune cell acts more flexibly than previously thought - with potential for new therapeutic approaches. As part of the innate immune system, dendritic cells are in the body's first...
- Carrying the Chinese trade name of Wan Ti Le, the tablets are indicated for individuals who have either insufficient response or cannot tolerate phosphorus binders. They are claimed The post China’s NMPA approves Fosun’s NDA of Tenapanor...
- The decision paves the way for the commercial launch of the injection in the Canadian market. It supports the company’s aim to broaden biosimilar accessibility in the worldwide The post Health Canada grants marketing authorisation to...
- Yesintek is claimed to be one of the first Stelara (ustekinumab) biosimilar market entrants in the US. The therapy gained approval for treating various conditions which includes Crohn’s The post Biocon Biologics launches...
- GSK plc (LSE/NYSE: GSK) announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal...
- Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill switches" that can be triggered to stop the bacteria after they activate an immune...
- Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for melanoma. Since then, many therapeutic - as opposed to preventive - cancer vaccines have been in development,...
- A fully human anti-cluster of differentiation (CD3) monoclonal antibody, intranasal foralumab is tailored to modulate the immune system and reduce neuroinflammation, which is a significant factor in the The post Tiziana partners with...
- New research suggests that antidepressants can accelerate cognitive decline in people with dementia. At the same time, some drugs appear to be less harmful than others, which can help doctors make better treatment decisions, according to...
- This marks Epkinly as the first subcutaneously administered T-cell engaging bispecific antibody approved in the country for R/R follicular lymphoma as well as R/R large B-cell lymphomas. The The post Genmab’s epcoritamab gains...
- Roche (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is...
- For the average person, living at high altitude - where oxygen is sparser than at sea level - can have health benefits ranging from lower rates of heart disease to increased endurance. But for those born with inherited mitochondrial...
- AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that investigational gene therapy AB-1005 for the treatment of Parkinson's disease (PD) has been granted...
- A research team co-led by scientists at the University of Arizona College of Medicine - Tucson found that an osteoporosis drug might counter a rare genetic mutation underlying a type of heart disease. The results were published today in...
- Scientists at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have developed a ground-breaking technique to deliver therapeutic molecules directly to the brain, bypassing the blood-brain barrier. Led...
- When a tumour develops, it creates a structure around itself called the tumour stroma, within which blood and lymphatic vessels ensure nutritional and respiratory biological exchanges. Lymphangiogenesis, i.e. the development of lymphatic...
- Physical activity is not only important for fitness, but also for health. This is confirmed by a new study conducted under the direction of Prof. Dr. Maximilian Kleinert at the German Institute of Human Nutrition Potsdam-Rehbrücke...
- Antibiotics are indispensable for treating bacterial infections. But why are they sometimes ineffective, even when the bacteria are not resistant? In their latest study published in the journal Nature, researchers from the University of...
- Doctors at Queen Mary University of London, Barts Health NHS Trust, and University College London have led the development of a simple, minimally invasive Targeted Thermal Therapy (Triple T) that has the potential to transform medical...
- An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found. Results published in the Journal of Crohn's and Colitis revealed that an antibiotic called...
- After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD). This rare disease has an especially poor...
- Tuberculosis is a serious global health threat that infected more than 10 million people in 2022. Spread through the air and into the lungs, the pathogen that causes "TB" can lead to chronic cough, chest pains, fatigue, fever and weight...
- Many people would like to delay or even stop the aging process. Previous clinical studies have shown that a reduced calorie intake can slow down the aging process in humans. Taking vitamin D or omega-3 fatty acids has also shown...
- Secondary prevention medications for cardiovascular diseases (CVD) are underused globally and additional strategies to increase their use are needed to improve CVD management and reduce premature mortality rates, according to study...
- For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week. "It's been a tremendous success and has proven to be...
- The inflammatory disease affects around one in 2,000 people in the US
- Results from a mid-stage of the candidate were recently published in the NEJM
- The skin disease affects an estimated 1% of the population in most studied countries
- The collaboration will first focus on developing products for long COVID and ME/CFS
- Researchers used a technique to identify specific molecular details of biotin-labelled proteins
- Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
- The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
- The drug could prevent conditions including diabetic eye and kidney disease in diabetes
- The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
- The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
- There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
- Approximately one in 10,000 people are affected by the genetic blood clotting disorder
- The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
- F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
- Both companies will leverage their autologous CAR-T cell therapy programmes
- Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
- Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
- Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
- Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
- Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22